No Data
Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?
UCB Gets Expanded FDA Approval for Psoriasis Drug Bimzelx
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $75
LifeSci Capital analyst Rami Katkhuda maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $75.According to TipRanks data, the analyst has a success
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $104
Oppenheimer analyst Andreas Argyrides maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $104.According to TipRanks data, the analyst has a success
Leerink Partners Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $73
Leerink Partners analyst Thomas Smith maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $73.According to TipRanks data, the analyst has a success
Jefferies Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $65
Jefferies analyst Kelly Shi maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and adjusts the target price from $66 to $65.According to TipRanks data, the analyst has a success